B7-H3(4Ig) or B7-H3b has two additional Ig-like domains (one V- type and one C- type) and shows a ubiquituous expression pattern. B7-H3(4Ig) is expressed on dendritic cells as well as activated T, B and NK cells. Human (4Ig) binding to an undefined receptor has shown to be inhibitory to NK cell illing and cytokine release. It also seems to be required for late stage osteoblast differentiation.
Sequence
Human B7-H3(4Ig) [B7-H3b] (aa 27-461) is fused at the C-terminus to a His-tag.
Crossreactivity
Human
Biological Activity
Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells.
MW
~65kDa (SDS-PAGE)
Purity
≥95% (SDS-PAGE)
Endotoxin Content
<0.01EU/μg protein (LAL test; Lonza).
Reconstitution
Reconstitute 50µg vial with 100 µl sterile water to a concentration of 0.5mg/ml. Add 1X PBS to the desired protein concentration.
CD28 (human):Fc (human) (rec.) | CHI-HF-210CD28
CD28 and CTLA-4 together with their ligands, CD80 (B7-1) and CD86 (B7-2), constitute one of the dominantcostimulatory pathways that regulate T and B...
CD28 (human):Fc (human) (rec.) | CHI-HF-210CD28
CD152 [CTLA-4] and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell...